Page 51 - AN-3-4

Advanced Neurology Anticoagulants as neuroprotective therapeutics

162. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban doi: 10.1007/s11239-016-1446-0
versus warfarin in patients with atrial fibrillation according 165. Rivard L, Khairy P, Talajic M, et al. Blinded randomized
to prior warfarin use: Results from the apixaban for trial of anticoagulation to prevent ischemic stroke and
reduction in stroke and other thromboembolic events in neurodegenerative impairment in Atrial Fibrillation
atrial fibrillation trial. N Engl J Med. 2011;365(11):981-992. (BRAIN-AF): Methods and design. Can J Cardiol.
doi: 10.1016/j.ahj.2013.05.016 2019;35(8):1069-1077.
163. Lin KJ, Singer DE, Bykov K, et al. Comparative effectiveness doi: 10.1016/j.cjca.2019.04.022
and safety of oral anticoagulants by dementia status in 166. ClinicalTrials.Gov. A Novel Therapeutic Target for Alzheimer’s
older patients with atrial fibrillation. JAMA Network Open. disease in Men and Women 50-85 Years of Age. Available
2023;6(3):e234086. from: https://clinicaltrials.gov/ct2/show/NCT03752294

doi: 10.1001/jamanetworkopen.2023.4086 [Last accessed on 2024 Feb 12].
164. Zirlik A, Bode C. Vitamin K antagonists: Relative strengths 167. Therriault J, Schindler S.E, Salvado G, et al. Biomarker-
and weaknesses vs. direct oral anticoagulants for stroke based staging of Alzheimer disease: Rationale and clinical
prevention in patients with atrial fibrillation. J Thromb applications. Nat Rev Neurol. 2024;20(4):232-244.
Thrombolysis. 2017;43(3):365-379. doi: 10.1038/s41582-024-00942-2

Volume 3 Issue 4 (2024) 33 doi: 10.36922/an.3799